Oregon wants to get out of covering drugs like Aduhelm in Medicaid – STAT

What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis.
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

• Daily reporting and analysis
• The most comprehensive industry coverage from a powerhouse team of reporters
• Subscriber-only newsletters
• Daily newsletters to brief you on the most important industry news of the day
• STAT+ Conversations
• Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
• Exclusive industry events
• Premium access to subscriber-only networking events around the country
• The best reporters in the industry
• The most trusted and well-connected newsroom in the health care industry
• And much more
• Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.